Method of treating an allergy with allergen-specific monoclonal antibodies
Fully human antibodies targeting Fel d1 allergen block its binding to IgE on mast cells and basophils, effectively mitigating allergic responses by inhibiting histamine release, addressing the inadequacies of existing treatments.
HK40134953APending Publication Date: 2026-07-17REGENERON PHARMACEUTICALS INC
Patent Information
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- REGENERON PHARMACEUTICALS INC
- Filing Date
- 2026-04-27
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Current treatments for allergies, particularly those caused by cat allergen Fel d1, are inadequate in preventing the binding of the allergen to IgE on mast cells and basophils, leading to the release of histamine and other inflammatory mediators, which exacerbates allergic reactions.
Method used
Administering fully human antibodies that specifically bind to Fel d1 allergen in vivo to prevent its interaction with pre-formed IgE on mast cells and basophils, thereby blocking the release of histamine and other inflammatory mediators.
Benefits of technology
The antibodies effectively inhibit the allergen-IgE interaction, reducing adverse reactions in sensitized individuals by preventing the release of histamine and other inflammatory mediators.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000070_0000 
Figure 00000071_0000 
Figure 00000071_0001
Abstract
The present invention provides methods for treating an allergy by administering one or more antibodies that bind specifically to the allergen. In certain embodiments, the antibodies useful for treating an allergen, bind specifically to the cat allergen, Fel d1. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and / or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals.
Need to check novelty before this filing date? Find Prior Art